PharmStar Pharmaceuticals, Inc. Announces Aquaprin Marketing Campaign
WILSON, N.C., Dec. 21, 2011 /PRNewswire/ -- PharmStar Pharmaceuticals, Inc., (Pink Sheets: PHAR) (the "Company"), today announced the rollout of its initial marketing plan for the introduction of its signature product, Aquaprin.
The marketing plan includes a multi-city tour in the United States to present the product to the medical community. This presentation is designed specifically for those that have a need to understand the advantages and benefits of the liquid aspirin derivative, as well as the line extension products that will be offered using the Aquaprin technology.
In discussing the tour, CEO Howard Phykitt said, "It is our belief that Aquaprin can be the pain reliever that most people will reach for when facing aches and pains. Doctors and pharmacists will want to fully understand the product, and we need such a forum to answer questions. Medical professionals have a need to know about this new tool that we can provide for their toolbox."
The audience for each presentation will be by invitation only, and will include professionals that are connected to the medical industry, as well as financial professionals. The tour will kick off in Los Angeles, CA on January 18, 2012, to be followed by presentations in Raleigh, NC; Miami, FL; and Dallas, TX over the successive eight weeks. The remainder of the tour will be announced as dates are finalized. The presentations will be made by Mr. Phykitt, the inventor of the technology used to make Aquaprin.
About PharmStar Pharmaceuticals
PharmStar Pharmaceuticals, Inc. ("PharmStar") is a U.S.-based drug development, manufacturing and marketing company and the innovator of the FDA-approved liquid pain reliever, Aquaprin. In development since 1993 with over $3 million invested to-date, Aquaprin is a liquid derivative of aspirin, and is now ready for commercialization. Aquaprin's unique, multiple patent-pending formulas are designed to dissolve nearly instantly in just 1.5 ounces or more of water. This enables the product to be absorbed into the bloodstream up to 10 times faster than traditional OTC pain relievers, and with little to no stomach upset.
PharmStar initially plans to sell Aquaprin directly to nursing homes, outpatient and health care clinics, emergency units of hospitals nationwide, as well as retail distribution in selected local markets and third-party websites to be announced. All package engineering, product stability; shelf life testing and quality control research has been completed. PharmStar's headquarters are located in Wilson, NC.
Forward-Looking Statements Disclosure
This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "will," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
SOURCE PharmStar Pharmaceuticals, Inc.